The overall mission of the UCSD/UCLA DRC centers on supporting research in the prevention and treatment of diabetes and its complications to ultimately improve the lives of patients. For the past 17 years, our DRC has been unique in linking together the diabetes/metabolism research activities of two major universities within the UC system and their affiliated institutions in Southern California. This effort has fostered new collaborations and interactions between outstanding scientists within and across these institutions. Our research base is comprised of the following focus areas: Nuclear Receptors, Cell Signaling, Metabolism, Diabetes Complications, and Islet/Beta Cell Biology. Each of these areas has outstanding leaders who facilitate interactions and sharing of resources. The DRC has played an important role in promoting the careers of young scientists as they move on to the status of independent investigators by awarding pilot and feasibility grants. As an acknowledgement of our success in this effort, UCSD and UCLA have agreed to provide over $100,000/year in additional unrestricted funds to augment our P&F program. The DRC will continue to advance scientific and intellectual interactions by organizing and facilitating meetings, lectures, and mentoring efforts that are part of our Enrichment Program. We will further accelerate diabetes research at the DRC Institutions by providing state-of-the-art services through five cutting edge cores: A) The Transgenic and Knockout Mouse Core, B) Metabolic and Molecular Physiology Core, C) Epigenetics and Genomics Core, D) Human Genetics Core, and E) Targeted Pathway Analysis Core. All of our research cores have been updated with new services and latest technologies in the upcoming project period to reflect the needs of our faculty, and the many advances in this field as they relate to diabetes and metabolism research. Our efforts to support the cores and facilitate collaboration have been successful, as can be judged by the numerous collaborative publications in high impact journals and the substantial peer review grant support our faculty have accrued. The current competitive renewal application includes many new scientific and technological advancements, including the incorporation of novel genomic, proteomic, and metabolomics services that are now available to our members in a streamlined and seamless fashion. Our future plans include the continued seamless integration of research at all participating institutions to enhance technology and research capability within the DRC, to promote the careers of promising young investigators through our successful P&F Program, and to accelerate translational research activity and collaborations through interactions with the CTSA programs at both institutions.

Public Health Relevance

The UCSD/UCLA DRC will enhance research into the etiology, pathophysiology, treatment, and prevention of diabetes and its complications through facilitation of scientific exchange, and advancement of the outstanding scientific faculty comprising our research base, by providing access to novel biomedical research cores and promoting the careers of young scientists. This will ultimately improve the lives of patients with diabetes, who will benefit from the advancements the center will generate.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK063491-18
Application #
9961907
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Hyde, James F
Project Start
2002-12-01
Project End
2025-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Wang, Bo; Rong, Xin; Palladino, Elisa N D et al. (2018) Phospholipid Remodeling and Cholesterol Availability Regulate Intestinal Stemness and Tumorigenesis. Cell Stem Cell 22:206-220.e4
Gong, J; Nishimura, K K; Fernandez-Rhodes, L et al. (2018) Trans-ethnic analysis of metabochip data identifies two new loci associated with BMI. Int J Obes (Lond) 42:384-390
Jo Hodonsky, Chani; Schurmann, Claudia; Schick, Ursula M et al. (2018) Generalization and fine mapping of red blood cell trait genetic associations to multi-ethnic populations: The PAGE Study. Am J Hematol :
Hernandez-Carretero, A; Weber, N; La Frano, M R et al. (2018) Obesity-induced changes in lipid mediators persist after weight loss. Int J Obes (Lond) 42:728-736
Prohaska, Thomas A; Que, Xuchu; Diehl, Cody J et al. (2018) Massively Parallel Sequencing of Peritoneal and Splenic B Cell Repertoires Highlights Unique Properties of B-1 Cell Antibodies. J Immunol 200:1702-1717
Bihlmeyer, Nathan A; Brody, Jennifer A; Smith, Albert Vernon et al. (2018) ExomeChip-Wide Analysis of 95 626 Individuals Identifies 10 Novel Loci Associated With QT and JT Intervals. Circ Genom Precis Med 11:e001758
Robinson-Cohen, Cassianne; Bartz, Traci M; Lai, Dongbing et al. (2018) Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. J Am Soc Nephrol 29:2583-2592
Napier, Melanie D; Franceschini, Nora; Gondalia, Rahul et al. (2018) Genome-wide association study and meta-analysis identify loci associated with ventricular and supraventricular ectopy. Sci Rep 8:5675
Bhambhani, Vijeta; Kizer, Jorge R; Lima, Joao A C et al. (2018) Predictors and outcomes of heart failure with mid-range ejection fraction. Eur J Heart Fail 20:651-659
Riopel, Matthew; Seo, Jong Bae; Bandyopadhyay, Gautam K et al. (2018) Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function. J Clin Invest 128:1458-1470

Showing the most recent 10 out of 926 publications